→
Amgen Inc (AMGN) is showing promising fundamentals with an impressive EPS growth of 88.23% year-over-year and a robust market cap of $192.56B. The current price of $355.28 is well below its 52-week high of $391.145, representing a potential upside of 10.1%. Furthermore, Amgen's strong return on equity (ROE) of 89.06% indicates efficient management, making this a compelling buy.
Investors should consider buying AMGN for its strong growth potential and solid fundamentals.
Amgen's robust EPS growth of 88.23% suggests strong earnings momentum, which could drive further stock appreciation. Additionally, the company's dividend yield of 2.66% provides a steady income stream for investors, enhancing its attractiveness.
The company faces potential challenges, as seen in the news regarding the FDA withdrawal fight for its $500 million Tavneos. Moreover, the high D/E ratio of 5.78 raises concerns about financial leverage and could deter risk-averse investors.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Amgen Inc (AMGN) is showing promising fundamentals with an impressive EPS growth of 88.23% year-over-year and a robust market cap of $192.56B. The current price of $355.28 is well below its 52-week high of $391.145, representing a potential upside of 10.1%. Furthermore, Amgen's strong return on equity (ROE) of 89.06% indicates efficient management, making this a compelling buy.
The company faces potential challenges, as seen in the news regarding the FDA withdrawal fight for its $500 million Tavneos. Moreover, the high D/E ratio of 5.78 raises concerns about financial leverage and could deter risk-averse investors.
Amgen's robust EPS growth of 88.23% suggests strong earnings momentum, which could drive further stock appreciation. Additionally, the company's dividend yield of 2.66% provides a steady income stream for investors, enhancing its attractiveness.
Amgen's robust EPS growth of 88.23% suggests strong earnings momentum, which could drive further stock appreciation. Additionally, the company's dividend yield of 2.66% provides a steady income stream for investors, enhancing its attractiveness. The company faces potential challenges, as seen in the news regarding the FDA withdrawal fight for its $500 million Tavneos. Moreover, the high D/E ratio of 5.78 raises concerns about financial leverage and could deter risk-averse investors.
Amgen Inc (AMGN) is showing promising fundamentals with an impressive EPS growth of 88.23% year-over-year and a robust market cap of $192.56B. The current price of $355.28 is well below its 52-week high of $391.145, representing a potential upside of 10.1%. Furthermore, Amgen's strong return on equity (ROE) of 89.06% indicates efficient management, making this a compelling buy.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for AMGN at helmterminal.dev/analyze/AMGN, updated continuously during US market hours. No signup required.